secwatch.observer — SEC 8-K summary
======================================

Issuer:     HOOKIPA Pharma Inc. (HOOK)
CIK:        0001760542
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001558370-24-011626
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Hookipa reports Q2 net loss $19.1M; cash $77.4M; eseba-vec Phase 2/3 trial on track for Q4 2024
--------------------------------------------------------------------------------

- Net loss of $19.1M for Q2 2024 vs $18.0M in Q2 2023; revenue $1.3M down from $2.7M.
- Cash, cash equivalents and restricted cash fell to $77.4M from $117.5M as of Dec 31, 2023.
- Malte Peters appointed CEO and Terry Coelho as EVP & CFO effective July 22, 2024.
- Eseba-vec (HB-200) AVALON-1 Phase 2/3 trial aligned with FDA; start expected Q4 2024.
- Received $5M milestone from Gilead for HB-500 HIV Phase 1b first dosing; $10M from Roche for HB-700 IND.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1760542/000155837024011626/0001558370-24-011626-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1760542/000155837024011626/hook-20240808x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-011626

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer